A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia

Simon Z. HeDepartment of Clinical Haematology and BMT Service, The Royal Melbourne Hospital, Melbourne, Australia;Department of Medicine at The Royal Melbourne Hospital, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Australia;The Walter and Eliza Hall Institute of Medical Research, Melbourne, AustraliaCorrespondence[email protected]

Samantha BusfieldCSL Research and Development, Melbourne, Australia

David S. RitchieDepartment of Clinical Haematology and BMT Service, The Royal Melbourne Hospital, Melbourne, Australia;Department of Medicine at The Royal Melbourne Hospital, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Australia;Peter MacCallum Cancer Centre, Melbourne, Australia;Victorian Comprehensive Cancer Centre, Melbourne, Australia

Mark S. HertzbergWestmead Hospital, Sydney, Australia;Prince of Wales Hospital, Sydney, Australia

Simon DurrantRoyal Brisbane and Women's Hospital, Brisbane, Australia

Ian D. LewisRoyal Adelaide Hospital, Adelaide, Australia

Paula MarltonPrincess Alexandra Hospital, Brisbane, Australia;University of Queensland School of Medicine, Queensland, Australia

Andrew J. McLachlanFaculty of Pharmacy and Centre for Education and Research on Ageing, University of Sydney and Concord Hospital, Sydney, Australia

Ian KerridgeWestmead Hospital, Sydney, Australia

Kenneth F. BradstockWestmead Hospital, Sydney, Australia

Glen KennedyRoyal Brisbane and Women's Hospital, Brisbane, Australia

Andrew W. BoydRoyal Brisbane and Women's Hospital, Brisbane, Australia;University of Queensland School of Medicine, Queensland, Australia;QIMR Berghofer Medical Research Institute, Queensland, Australia

Trina M. YeadonQIMR Berghofer Medical Research Institute, Queensland, Australia

Angel F. LopezCentre for Cancer Biology, University of South Australia, Adelaide, Australia

Hayley S. RamshawCentre for Cancer Biology, University of South Australia, Adelaide, Australia

Harry IlandRoyal Prince Alfred Hospital, Sydney, Australia

Simone BamfordCSL Research and Development, Melbourne, Australia

Megan BarndenCSL Research and Development, Melbourne, Australia

Mark DeWitteCSL Research and Development, Melbourne, Australia

Russell BasserCSL Research and Development, Melbourne, Australia

Andrew W. RobertsDepartment of Clinical Haematology and BMT Service, The Royal Melbourne Hospital, Melbourne, Australia;Department of Medicine at The Royal Melbourne Hospital, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Australia;The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia;Victorian Comprehensive Cancer Centre, Melbourne, Australia

show all

A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia

ilal_a_956316_sm4706.zip

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia

ilal_a_956316_sm4706.zip

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date